Key statistics
As of last trade Innoviva Inc (INVA:NSQ) traded at 21.98, -12.59% below its 52-week high of 25.15, set on Feb 26, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.11 |
|---|---|
| High | 22.11 |
| Low | 21.84 |
| Bid | 21.97 |
| Offer | 22.04 |
| Previous close | 22.18 |
| Average volume | 851.53k |
|---|---|
| Shares outstanding | 74.07m |
| Free float | 73.33m |
| P/E (TTM) | 7.34 |
| Market cap | 1.68bn USD |
| EPS (TTM) | 3.10 USD |
Data delayed at least 15 minutes, as of Mar 06 2026 15:27 GMT.
More ▼
- Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
- Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
- Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
